Close Menu

NEW YORK – Natera said on Thursday that it has received a final local coverage determination (LCD) from Medicare contractor Palmetto GBA for its Prospera organ transplant rejection test for kidney transplant patients.

Effective Feb. 3, 2020, the donor-derived cell-free DNA test will be covered for all kidney transplant recipients, including those with multiple kidney transplants, marking a coverage expansion from the initial draft LCD. The test identifies both T-cell mediated and antibody-mediated rejection.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.